Big Gain For Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. (ONCT:NASDAQ) jumped higher at $2.09, representing a gain of 47.2%. On Mon, Oct 21, 2024, ONCT:NASDAQ hit a New 2-Week High of $2.09. The stock appeared on our News Catalysts scanner on Wed, Oct 02, 2024 at 09:10 PM in the 'BIOTECH' category. From Mon, Oct 07, 2024, the stock recorded 40.00% Up Days and 45.45% Green Days
About Oncternal Therapeutics, Inc. (ONCT:NASDAQ)
GTx Inc is a biopharmaceutical company. It is involved in the business of discovery, development, and commercialization of small molecules for the treatment of cancer including treatment of breast and prostate cancer and other serious medical conditions such as Stress urinary incontinence and Duchenne muscular dystrophy. Its lead product candidate is Enobosarm. The company's strategy is focused on the further development of selective androgen receptor modulators.
Top 10 Gainers:
- Genprex, Inc. (GNPX:NASDAQ), 260.38%
- GRI Bio Inc Com (GRI:NASDAQ), 127.59%
- Siyata Mobile Inc. (SYTA:NASDAQ), 82.18%
- Sensei Biotherapeutics Inc. (SNSE:NASDAQ), 78.08%
- IN8bio Inc. (INAB:NASDAQ), 75.28%
- JE Cleantech Holdings Limited (JCSE:NASDAQ), 55.94%
- Spirit Airlines, Inc. (SAVE:NYSE), 53.06%
- Neo-Concept International Group Holdings Limited (NCI:NASDAQ), 48.57%
- Oncternal Therapeutics, Inc. (ONCT:NASDAQ), 47.18%
- Histogen Inc. (HSTO:NASDAQ), 41.18%